—Launch of Anti-Murine IgG and Streptavidin High Binding FA Screening Biosensors—
MENLO PARK, Calif. — August 13, 2007 — ForteBio, Inc., a leading developer of label-free, real-time systems for biomolecular interaction analysis, today announced two new product extensions to its Octet™ System. The Anti-Murine IgG Biosensor — Quantitation grade, and the Streptavidin High Binding FA Biosensor — Screening grade, extend the Octet System's concentration determination and kinetic analysis capabilities, respectively, broadening the product offering into additional research-focused applications.
“We are continually expanding our menu of surface chemistries to serve the growing demand for label-free detection in new areas of therapeutic research and development,” said Winnie Wan, President and Chief Executive Officer. “Since the launch of the Octet System less than two years ago, we have responded quickly to the needs of the research market by developing seven compatible biosensors that expand the system's applications in therapeutic development and bioprocessing.
The Anti-Murine IgG Biosensor — Quantitation grade, provides accurate concentration determination of mouse and rat sera or supernatants. With the Octet System, fast and accurate results for 96 samples can be achieved in 30 minutes. The Streptavidin High Binding FA Biosensor — Screening grade, provides triple the binding capacity for increased signal-to-noise ratios. These biosensors enable better kinetic screening and analysis of smaller proteins and fragment antibodies (Fabs). With increased ratios, custom quantitation assays for most proteins can also be developed.
The Octet System is a label-free, fluidics-free, real-time system for biomolecular interaction analysis of protein kinetics and Quantitation. It is currently used by pharmaceutical and biotechnology companies in applications ranging from target identification and validation to bioprocess development.
About ForteBio, Inc.
ForteBio is a venture-capital funded life science company providing analytical systems to accelerate the development of therapeutics. These systems enable real-time analysis of biomolecular interactions providing information on affinity, kinetics and concentration. Most importantly, ForteBio's analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California with a wholly owned subsidiary in Shanghai, China. For more information, please visit www.fortebio.com.
Contact Information 2:
Winnie Wan, Ph.D.
President and Chief Executive Officer